Last updated: May 29, 2026

Application No. 18/105,460

CONJUGATES COMPRISING REVERSIBLE LINKERS AND USES THEREOF

Non-Final OA

Filed

Feb 03, 2023

Priority

Aug 05, 2020 — EU 20189583.6 +2 more

Examiner

JOHNSON, CHRISTOPHER LINDSAY

Art Unit

1691

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Ascendis Pharma A/S

OA Round

1 (Non-Final)

This examiner grants 54% of cases after interview

— +73.3% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 24 resolved cases, 2023–2026

Examiner Intelligence

JOHNSON, CHRISTOPHER LINDSAY View full profile →

Grants 54% of resolved cases

Career Allowance Rate

13 granted / 24 resolved

-5.8% vs TC avg

Strong +73% interview lift

Without

With

+73.3%

Interview Lift

resolved cases with interview

Typical timeline

3y 3m

Avg Prosecution

28 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§103

59.6%

+19.6% vs TC avg

§102

13.5%

-26.5% vs TC avg

§112

11.2%

-28.8% vs TC avg

Black line = Tech Center average estimate • Based on career data from 24 resolved cases

Prosecution Timeline

Feb 03, 2023

Application Filed

Apr 01, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/709,556

Patent 12637426

1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS

4y 1m to grant Granted May 26, 2026

17/773,197

Patent 12637428

ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS

4y 0m to grant Granted May 26, 2026

17/595,711

Patent 12624022

HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITOR

4y 5m to grant Granted May 12, 2026

18/257,371

Patent 12624012

14-CHLORO-BETA-ELEMENE NITRIC OXIDE DONOR DERIVATIVE AND PREPARATION METHOD AND USE THEREOF

2y 11m to grant Granted May 12, 2026

19/026,681

Patent 12612402

NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF

1y 3m to grant Granted Apr 28, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

54%

Grant Probability

99%

With Interview (+73.3%)

3y 3m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 24 resolved cases by this examiner. Grant probability derived from career allowance rate.